Evidence of Higher Oxidative Status in Depression and Anxiety

G. Grases,1,2 M. A. Colom,1 R. A. Fernandez,3 A. Costa-Bauzá,3 and F. Grases3

1 Psychology and Neurology Center (CLONUS), 07014 Palma de Mallorca, Spain
2 Centro de Enseñanza Superior Alberto Giménez (CESAG), 07013 Palma de Mallorca, Spain
3 University Institute of Health Sciences Research (IUNICS-IdIsPa), University of Balearic Islands, 07122 Palma de Mallorca, Spain

Correspondence should be addressed to F. Grases; fgrases@uib.es

Received 5 February 2014; Revised 27 March 2014; Accepted 8 April 2014; Published 29 April 2014

Academic Editor: Luisa Minghetti

Copyright © 2014 G. Grases et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We use a simple method for evaluating antioxidative status, by measuring the redox potential of urine, and correlate the findings with measures of anxiety and depression. We include 63 individuals (28 males and 35 females aged between 20 and 65 years). The validated anxiety State-Trait Anxiety Inventory questionnaire and the validated BDI (Beck Depression Inventory) questionnaire were used to evaluate anxiety and depression. Antioxidative status was determined by measuring the redox potential of urine collected in standard conditions. Correlation of the antioxidant capacity of urines evaluated using the ferric ion/specific dye method or through redox potential using the platinum electrode demonstrated the suitability of this last procedure. We found that normal anxiety state values corresponded to low urine redox potentials, whereas higher anxiety states were associated with high urinary redox potential. We also found that individuals with normal BDI values had significantly lower urine redox potentials than individuals with higher BDI values.

1. Introduction

Oxidative stress is a consequence of excessive production of free radicals and also due to the failure of the antioxidant defense mechanism that protects the cells removing free radicals [1]. The antioxidant system is integrated by two types of substances: the enzymatic and the nonenzymatic antioxidants [2, 3]. The enzymatic antioxidants are macro-molecules (high molecular weight) as superoxide dismutase, glutathione peroxidase, glutathione reductase, glutathione transferase, and catalase. The nonenzymatic antioxidants are little molecules (low molecular weight) as ascorbic acid, vitamin E, uric acid, N-acetyl-cysteine, flavonoids, carotenoids, polyphenols, and phytate. All these little molecules can be filtered by the kidney and can appear in urine. When an excess of free radicals is generated and/or exceeds the antioxidant defense mechanism, this causes important cell damage through alteration of DNA, protein, and lipids and obviously this causes a consumption of antioxidants and oxidative stress appears [1, 4].

Oxidative stress has been associated with the pathogenesis of several diseases [5, 6]. Thus oxidative stress may be a pathogenic factor in many psychiatric disorders [7, 8] due to the high oxygen consumption and lipid-rich constitution of the brain [9, 10] and has recently been implicated in depression and anxiety [11, 12]. Depression and anxiety are related to lowered plasma concentrations of antioxidants, such as vitamin E, tryptophan, tyrosine, albumin, zinc, glutathione, and CoQ10, and lowered antioxidative enzyme activities [11–13]. The deficit of antioxidants can decrease the protection against reactive oxygen species (ROS) and reactive nitrogen species, inducing oxidative and nitrosative stress and damage to fatty acids, proteins, DNA, and mitochondria [11]. The 8-hydroxy-2′-deoxyguanosine in urine is a biomarker for oxidative DNA damage [14, 15]. Thus it has been demonstrated that major depression is accompanied by increased 8-hydroxy-2′-deoxyguanosine levels, indicating oxidative damage to DNA by ROS [16–18]. Increased ROS in depression is also demonstrated by increased levels of malondialdehyde and arachidonic acid [11]. There is also evidence that major depression causes (auto)immune responses [19]. Thus depression is associated with increased levels of plasma IgG antibodies against oxidized LDL and increased IgM-mediated immune response against membrane fatty
2. Material and Methods

Sixty-three volunteers (28 males and 35 females), ranging in age from 20 to 65 years, were selected by the Psychology and Neurology Center (CLONUS). These individuals were recruited by CLONUS among patients and volunteers that accomplished the following inclusion and exclusion criteria.

(i) Patients with severe mental health disorders (e.g., schizophrenia, major depression, bipolar disorder, and obsessive-compulsive disorder) were excluded. Only patients with a diagnosis of anxiety, depressive disorders, marital conflicts, or behavioral problems were included.

(ii) Participants consuming antioxidant supplements or omega-3 PUFAs were excluded.

(iii) Participants with severe health problems (e.g., cancer, serious cardiopathy) that need chronic pharmacologic treatment were excluded.

(iv) Participants with addiction to alcohol or drugs were excluded.

All participants were not undergoing pharmacological treatment during urine collection and were on an unrestricted diet during urine collection.

All participants were Caucasian and belonging to median-high social status. Each participant provided written informed consent, and the institutional review board of the Balearic Islands Community approved the study (number IB 1912/12 PI).

2.1. Anxiety and Depression Questionnaires. The validated anxiety State-Trait Anxiety Inventory (STAI) questionnaire [23] was used to evaluate state (STAIE) anxiety (A/E). A/E < 22.00 were considered normal anxiety state values and A/E ≥ 22.00 were considered high anxiety state values. The validated BDI (Beck Depression Inventory) questionnaire [24] was used to assess depression. BDI < 10.00 were considered normal values and BDI ≥ 10.00 were considered light-moderate depression values.

2.2. Measurement of the Antioxidant Capacity of Urine Samples. All subjects were on free diet, and none was receiving pharmacological treatment at the time of urine collection. After an overnight fast, two-hour urine samples were collected early in the morning, after discarding the first micturition. This urine was used to measure redox potential because this measurement better represents the urinary basal redox potential since it is less affected by dietary factors. Each urine sample was immediately cooled to room temperature (25°C), and the redox potential was measured using a Crison potentiometer, with a platinum electrode as the working electrode and a saturated calomel electrode as the reference electrode. For comparative purposes, the antioxidant capacity of the urines was also evaluated using ferric ion and a specific dye (1,10-fenetrolone) [25, 26].

2.3. Statistical Analyses. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS, version 11.0 for Windows, Chicago, IL, USA). The Kolmogorov-Smirnov test was performed to evaluate the normality of the variables. Anxiety states were classified in two groups: normal (A/E < 22.00) and high anxiety states (A/E ≥ 22.00). Also two depression groups were considered: no depression (BDI < 10.00) and light-moderate depression (BDI ≥ 10.00). Between groups, differences were assessed using parametric Student’s t-tests for quantitative variables with normal distribution, non-parametric Mann-Whitney U tests for quantitative variables with nonnormal distribution, and Chi-square tests for qualitative variables. A P value < 0.05 was considered statistically significant.

3. Results

In Figure 1 the oxidant capacity of urines measured using ferric ion and 1,10-fenetrolone and through the direct evaluation of redox potential by means of a platinum electrode is represented. The results demonstrated a good correlation between both measures.

When we measured urine redox potentials in individuals with normal and high anxiety (Figure 2), we found that normal anxiety state values (A/E < 22) corresponded to low mean urine redox potentials (28.8 mV, SD 35.8), whereas higher anxiety states (A/E ≥ 22) were associated with mean urinary redox potential of 68.12 mV (SD 34.8) (P < 0.001).

We also assessed urine redox potentials as a function of depression (Figure 3). We found that individuals with normal BDI values had significantly lower mean urine redox potentials than individuals with higher BDI values (35.6 mV, SD 36.27 versus 71.7 mV, SD 36.9, P < 0.001).
Figure 1: Linear regression between antioxidant capacity (mM Fe(II)) versus redox potential values. The dotted lines are the lines best fit. The solid lines are its 95% of confidence bands. Equation: $y = -0.073x + 16.941$, $R = 0.522$, $P < 0.001$.

Figure 2: Urinary redox potentials for normal and high anxiety states.

Table 1: Age distribution (mean and standard deviation) of the different Anxiety-State and Depression groups.

|                | Age (years) | N  | Mean | SD  |
|----------------|-------------|----|------|-----|
| Anxiety-State  |             |    |      |     |
| < 22,00        | 31          | 37.5| 13.7 |
| ≥ 22,00        | 32          | 41.5| 13.1 |
| Depression     |             |    |      |     |
| < 10,00        | 40          | 38.9| 13.6 |
| ≥ 10,00        | 23          | 40.6| 13.2 |

As can be seen in Table 1, no statistically significant differences were observed between groups of normal or higher anxiety or between groups of normal or higher BDI values.

Linear regression between Anxiety-State and Depression versus redox potential was analyzed in each case. The obtained results are shown in Figure 4. As can be seen, in both cases, positive linear relationships were found between both clinical scores and urinary redox potential values (Anxiety-State: $Y = 15.385 + 0.182X$, $R = 0.475$, $P < 0.001$. Depression: $Y = 4.926 + 0.073X$, $R = 0.463$, $P < 0.001$).

4. Discussion

The direct measurement of free radical concentrations is very difficult due to their short half-life and low concentrations. Consequently, measurements of the metabolites of ROS, antioxidant enzyme activities, antioxidant concentrations in blood, and markers of oxidative damage, including DNA damage, lipid peroxidation, and protein carbonylation, are used to quantify levels of oxidative stress [10]. Several procedures are available to determine the global antioxidative capacity of a biological fluid. A commonly used methodology is based on the reaction between the antioxidant present in the sample and ferric ions. The antioxidants present in the sample reduce the ferric ion and the formed ferrous ion complexes a specific dye forming a colored product. Intensity of the color, which is associated to the amount of antioxidant present in the sample, is measured spectrophotometrically [25]. The redox potential of a fluid is a measure of its tendency to act as an oxidizing or reducing media, with a more negative potential indicating a greater reducing capacity or antioxidant activity. In contrast, oxidizing media will have a higher positive redox potential. Due to this, the decrease in the fluid antioxidant status must be reflected by an increase in the fluid redox potential. Correlation of the antioxidant capacity of urines evaluated using the ferric ion/specific dye method [25, 26] or through redox potential using the platinum electrode demonstrated the suitability of this last procedure that was not used before for this purpose. Urine, a product of blood filtration, reflects the composition of blood, including molecules of low molecular weight as vitamins and other antioxidant molecules. Consequently, a deficiency in antioxidants will be reflected in urine composition and the corresponding urinary redox potential, in such a way that individuals with a high oxidative stress will excrete urine with low antioxidant capacity and high redox potential values. The results of this study demonstrate that higher anxiety or depression status of individuals was associated with higher...
urinary redox potentials. Consequently, our results suggest that individuals with anxiety or depression are deficient in antioxidants, indicative of increased oxidative stress.

Conflict of Interests

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by the project Grant CTQ2010-18271/PPQ from the Ministerio de Ciencia e Innovación (Gobierno de España), FEDER funds (European Union), and the project Grant 9/2011 from the Conselleria d’Educació, Cultura i Universitat (Govern de les Illes Balears).

References

[1] J. M. McCord, “Human disease, free radicals, and the oxidant/antioxidant balance,” Clinical Biochemistry, vol. 26, no. 5, pp. 351–357, 1993.
[2] J. M. Mates, C. Perez-Gomez, and I. N. de Castro, “Antioxidant enzymes and human diseases,” Clinical Biochemistry, vol. 32, no. 8, pp. 595–603, 1999.
[3] H. E. Seifried, D. E. Anderson, E. I. Fisher, and J. A. Milner, “A review of the interaction among dietary antioxidants and reactive oxygen species,” Journal of Nutritional Biochemistry, vol. 18, no. 9, pp. 567–579, 2007.
[4] J. M. C. Gutteridge, “Lipid peroxidation and antioxidants as biomarkers of tissue damage,” Clinical Chemistry, vol. 41, no. 12, pp. 1819–1828, 1995.
[5] P. Kovacic and R. Somanathan, “Redox processes in neurodegenerative disease involving reactive oxygen species,” Current Neuropharmacology, vol. 10, no. 4, pp. 289–302, 2012.
[6] M. L. Wahlqvist, “Antioxidant relevance to human health,” Asia Pacific Journal of Clinical Nutrition, vol. 22, no. 2, pp. 171–176, 2013.
[7] J. Bouayed, H. Rammal, and R. Soulimani, “Oxidative stress and anxiety relationship and cellular pathways,” Oxidative Medicine and Cellular Longevity, vol. 2, no. 2, pp. 63–67, 2009.
[8] I. Hovatta, J. Juhila, and J. Donner, “Oxidative stress in anxiety and comorbid disorders,” Neuroscience Research, vol. 68, no. 4, pp. 261–275, 2010.
[9] B. Halliwell, “Oxidative stress and neurodegeneration: where are we now?” Journal of Neurochemistry, vol. 97, no. 6, pp. 1634–1658, 2006.
[10] M. Berk, F. Ng, O. Dean, S. Dodd, and A. I. Bush, “Glutathione: a novel treatment target in psychiatry,” Trends in Pharmacological Sciences, vol. 29, no. 7, pp. 346–351, 2008.
[11] M. Maes, P. Galecki, Y. S. Chang, and M. Berk, “A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 676–692, 2011.
[12] G. Scapagnini, S. Davinelli, F. Dragino, A. de Lorenzo, and G. Oriani, “Antioxidants as antidepressants: fact or fiction?” CNS Drugs, vol. 26, no. 6, pp. 477–490, 2012.
[13] O. Erel, “A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation,” Clinical Biochemistry, vol. 37, no. 4, pp. 277–285, 2004.
[14] L. L. Wu, C. C. Chiou, P. Y. Chang, and J. T. Wu, “Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetes,” Clinica Chimica Acta, vol. 339, no. 1-2, pp. 1–9, 2004.
[15] A. Valavanidis, T. Vlachogiannis, and C. Fiotakis, “8-hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis,” Journal of Environmental Science and Health C: Environmental Carcinogenesis & Ecotoxicology Reviews, vol. 27, no. 2, pp. 120–139, 2009.
[16] M. J. Forlenza and G. E. Miller, “Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression,” Psychosomatic Medicine, vol. 68, no. 1, pp. 1–7, 2006.
[17] Y. C. Wei, F. L. Zhou, D. L. He et al., “The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma,” *Journal of Psychosomatic Research*, vol. 66, no. 3, pp. 259–266, 2009.

[18] M. Maes, I. Mihaylova, M. Kubera, M. Uytterhoeven, N. Vrydags, and E. Bosmans, “Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome,” *Neuroendocrinology Letters*, vol. 30, no. 6, pp. 715–722, 2009.

[19] M. Maes, I. Mihaylova, M. Kubera, M. Uytterhoeven, N. Vrydags, and E. Bosmans, “Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease,” *Journal of Affective Disorders*, vol. 125, no. 1–3, pp. 287–294, 2010.

[20] H. Rammal, J. Bouayed, C. Younos, and R. Soulimani, “The impact of high anxiety level on the oxidative status of mouse peripheral blood lymphocytes, granulocytes and monocytes,” *European Journal of Pharmacology*, vol. 589, no. 1–3, pp. 173–175, 2008.

[21] G. Lucca, C. M. Comim, S. S. Valvassori et al., “Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm,” *Journal of Psychiatric Research*, vol. 43, no. 9, pp. 864–869, 2009.

[22] L. Stafford and M. Berk, “The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression?” *Journal of Clinical Psychiatry*, vol. 72, no. 9, pp. 1229–1235, 2011.

[23] C. D. Spielberger, R. L. Gorsuch, and R. E. Lushene, *State-Trait Anxiety Inventory Questionnaire*, Consulting Psychologists Press, Palo Alto, Calif, USA, 1968, Validated by Department I+D TEA Editions S.A., Madrid, Spain, 1982.

[24] A. T. Beck, A. J. Rush, B. F. Shaw, G. Emery, and Beck Depresión Inventory, *Cognitive Therapy of Depression*, Guilford Press, New York, NY, USA, 1979, Trad. esp. en Bilbao: Desclée de Brouwer, 1983.

[25] I. F. Benzie and J. J. Strain, “The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay,” *Analytical Biochemistry*, vol. 239, no. 1, pp. 70–76, 1996.

[26] W. A. Hayes, D. S. Mills, R. F. Neville, J. Kiddie, and L. M. Collins, “Determination of the molar extinction coefficient for the ferric reducing/antioxidant power assay,” *Analytical Biochemistry*, vol. 416, no. 2, pp. 202–205, 2011.